PDF herunterladen
CC BY 4.0 · Indian J Med Paediatr Oncol 2023; 44(01): 084-092
DOI: 10.1055/s-0042-1759718
Review Article

Imaging Recommendations for Diagnosis, Staging, and Management of Renal Tumors

Chandan J Das
1   Department of Radiodiagnosis and Interventional Radiology, AIIMS, New Delhi, India
,
Ankita Aggarwal
2   Department of Radiodiagnosis, VMMC and SJH, New Delhi, India
,
Prabhjot Singh
3   Department of Urology, AIIMS, New Delhi, India
,
B Nayak
3   Department of Urology, AIIMS, New Delhi, India
,
Taruna Yadav 
4   Department of Radiodiagnosis, Jodhpur, Rajasthan, India
,
Anupam Lal
5   Department of Radiodiagnosis, PGI, Chandigarh, India
,
Ujjwal Gorsi
5   Department of Radiodiagnosis, PGI, Chandigarh, India
,
Atul Batra
6   Department of Medical Oncology, AIIMS, IRCH, New Delhi, India
,
Shamim Ahmed Shamim
7   Nuclear Medicine, AIIMS, New Delhi, India
,
Bijit Kumar Duara
8   Department of Radiodiagnosis, GMCH, Guwahati, Assam, India
,
Kevin Arulraj 
3   Department of Urology, AIIMS, New Delhi, India
,
Seema Kaushal
9   Department of Pathology, AIIMS, New Delhi, India
,
Amlesh Seth
3   Department of Urology, AIIMS, New Delhi, India
› Institutsangaben
› Weitere Informationen
   Lizenzen und Reprints

Abstract

Renal cell carcinomas accounts for 2% of all the cancers globally. Most of the renal tumors are detected incidentally. Ultrasound remains the main screening modality to evaluate the renal masses. A multi -phase contrast enhanced computer tomography is must for characterizing the renal lesions. Imaging plays an important role in staging, treatment planning and follow up of renal cancers. In this review , we discuss the imaging guidelines for the management of renal tumors.

Keywords

CT scan - MRI - PET-CT scan - renal cell carcinoma - ultrasound


Publikationsverlauf

Artikel online veröffentlicht:
06. März 2023

© 2023. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68 (06) 394-424
    Google Scholar
  • 2 Kabel AM, Zamzami F, Al-Talhi M, Al-Dwila K, Habib R. Renal cell carcinoma: insights into risk factors, diagnosis and management. J Cancer Research Treatment 2017; 5: 15-19
    Google Scholar
  • 3 Padala SA, Barsouk A, Thandra KC. et al. Epidemiology of renal cell carcinoma. World J Oncol 2020; 11 (03) 79-87
    Google Scholar
  • 4 Heng DYC, Xie W, Regan MM. et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol 2009; 27 (34) 5794-5799
    CrossrefPubMedGoogle Scholar
  • 5 Ko JJ, Xie W, Kroeger N. et al. The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study. Lancet Oncol 2015; 16 (03) 293-300
    CrossrefPubMedGoogle Scholar
  • 6 Bertolotto M, Bucci S, Valentino M, Currò F, Sachs C, Cova MA. Contrast-enhanced ultrasound for characterizing renal masses. Eur J Radiol 2018; 105: 41-48
    CrossrefPubMedGoogle Scholar
  • 7 Sidhu PS, Cantisani V, Dietrich CF. et al. The EFSUMB guidelines and recommendations for the clinical practice of contrast-enhanced ultrasound (CEUS) in non-hepatic applications: update 2017 (Long Version). Ultraschall Med 2018; 39 (02) e2-e44
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 8 Clevert D-A, Minaifar N, Weckbach S. et al. Multislice computed tomography versus contrast-enhanced ultrasound in evaluation of complex cystic renal masses using the Bosniak classification system. Clin Hemorheol Microcirc 2008; 39 (1-4): 171-178
    CrossrefPubMedGoogle Scholar
  • 9 Cantisani V, Bertolotto M, Clevert D-A. et al. EFSUMB 2020 proposal for a contrast-enhanced ultrasound-adapted Bosniak cyst categorization - position statement. Ultraschall Med 2021; 42 (02) 154-166
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 10 Wang ZJ, Nikolaidis P, Khatri G. et al; Expert Panel on Urologic Imaging. ACR Appropriateness Criteria® Indeterminate Renal Mass. J Am Coll Radiol 2020; 17 (11S): S415-S428
    CrossrefPubMedGoogle Scholar
  • 11 Meloni MF, Bertolotto M, Alberzoni C. et al. Follow-up after percutaneous radiofrequency ablation of renal cell carcinoma: contrast-enhanced sonography versus contrast-enhanced CT or MRI. AJR Am J Roentgenol 2008; 191 (04) 1233-1238
    CrossrefPubMedGoogle Scholar
  • 12 Vikram R, Beland MD, Blaufox MD. et al. ACR appropriateness criteria renal cell carcinoma staging. J Am Coll Radiol 2016; 13 (05) 518-525
    CrossrefPubMedGoogle Scholar
  • 13 Li Q, Wang Z, Ma X, Tang J, Luo Y. Diagnostic accuracy of contrast-enhanced ultrasound for detecting bland thrombus from inferior vena cava tumor thrombus in patients with renal cell carcinoma. Int Braz J Urol 2020; 46 (01) 92-100
    CrossrefPubMedGoogle Scholar
  • 14 Ljungberg B, Albiges L, Abu-Ghanem Y. et al. European Association of Urology Guidelines on Renal Cell Carcinoma: the 2022 update. Eur Urol 2022; 82 (04) 399-410
    CrossrefPubMedGoogle Scholar
  • 15 Ward RD, Tanaka H, Campbell SC, Remer EM. 2017 AUA renal mass and localized renal cancer guidelines: imaging implications. Radiographics 2018; 38 (07) 2021-2033
    CrossrefPubMedGoogle Scholar
  • 16 Pedrosa I, Cadeddu JA. How we do it: managing the indeterminate renal mass with the MRI clear cell likelihood score. Radiology 2022; 302 (02) 256-269
    CrossrefPubMedGoogle Scholar
  • 17 Silverman SG, Pedrosa I, Ellis JH. et al. Bosniak classification of cystic renal masses, Version 2019: an update proposal and needs assessment. Radiology 2019; 292 (02) 475-488
    CrossrefPubMedGoogle Scholar
  • 18 Birnbaum BA, Hindman N, Lee J, Babb JS. Renal cyst pseudoenhancement: influence of multidetector CT reconstruction algorithm and scanner type in phantom model. Radiology 2007; 244 (03) 767-775
    CrossrefPubMedGoogle Scholar
  • 19 Lim DJ, Carter MF. Computerized tomography in the preoperative staging for pulmonary metastases in patients with renal cell carcinoma. J Urol 1993; 150 (04) 1112-1114
    CrossrefPubMedGoogle Scholar
  • 20 Mano R, Vertosick E, Sankin AI. et al. Subcentimeter pulmonary nodules are not associated with disease progression in patients with renal cell carcinoma. J Urol 2015; 193 (03) 776-782
    CrossrefPubMedGoogle Scholar
  • 21 Kotecha RR, Flippot R, Nortman T. et al. Prognosis of incidental brain metastases in patients with advanced renal cell carcinoma. J Natl Compr Canc Netw 2021; 19 (04) 432-438
    CrossrefPubMedGoogle Scholar
  • 22 Dilauro M, Quon M, McInnes MDF. et al. Comparison of contrast-enhanced multiphase renal protocol CT versus MRI for diagnosis of papillary renal cell carcinoma. AJR Am J Roentgenol 2016; 206 (02) 319-325
    CrossrefPubMedGoogle Scholar
  • 23 Schieda N, Lim RS, McInnes MDF. et al. Characterization of small (<4cm) solid renal masses by computed tomography and magnetic resonance imaging: current evidence and further development. Diagn Interv Imaging 2018; 99 (7-8): 443-455
    CrossrefPubMedGoogle Scholar
  • 24 Herts BR, Silverman SG, Hindman NM. et al. Management of the incidental renal mass on CT: a white paper of the ACR incidental findings committee. J Am Coll Radiol 2018; 15 (02) 264-273
    CrossrefPubMedGoogle Scholar
  • 25 Krishna S, Schieda N, Pedrosa I. et al. Update on MRI of cystic renal masses including Bosniak Version 2019. J Magn Reson Imaging 2021; 54 (02) 341-356
    CrossrefPubMedGoogle Scholar
  • 26 Cheville JC, Lohse CM, Zincke H, Weaver AL, Blute ML. Comparisons of outcome and prognostic features among histologic subtypes of renal cell carcinoma. Am J Surg Pathol 2003; 27 (05) 612-624
    CrossrefPubMedGoogle Scholar
  • 27 Roy C, Sauer B, Lindner V, Lang H, Saussine C, Jacqmin D. MR imaging of papillary renal neoplasms: potential application for characterization of small renal masses. Eur Radiol 2007; 17 (01) 193-200
    CrossrefPubMedGoogle Scholar
  • 28 Cornelis F, Grenier N. Multiparametric magnetic resonance imaging of solid renal tumors: a practical algorithm. Semin Ultrasound CT MR 2017; 38 (01) 47-58
    CrossrefPubMedGoogle Scholar
  • 29 Tsili AC, Andriotis E, Gkeli MG. et al; Oncologic Imaging Subcommittee Working Group of the Hellenic Radiological Society. The role of imaging in the management of renal masses. Eur J Radiol 2021; 141: 109777 https://www.ejradiology.com/article/S0720-048X(21)00258-8/fulltext [Internet]
    CrossrefPubMedGoogle Scholar
  • 30 Yang C-W, Shen S-H, Chang Y-H. et al. Are there useful CT features to differentiate renal cell carcinoma from lipid-poor renal angiomyolipoma?. AJR Am J Roentgenol 2013; 201 (05) 1017-1028
    CrossrefPubMedGoogle Scholar
  • 31 Galia M, Albano D, Bruno A. et al. Imaging features of solid renal masses. Br J Radiol 2017; 90 (1077): 20170077
    CrossrefPubMedGoogle Scholar
  • 32 Low G, Huang G, Fu W, Moloo Z, Girgis S. Review of renal cell carcinoma and its common subtypes in radiology. World J Radiol 2016; 8 (05) 484-500
    CrossrefPubMedGoogle Scholar
  • 33 Servaes SE, Hoffer FA, Smith EA, Khanna G. Imaging of Wilms tumor: an update. Pediatr Radiol 2019; 49 (11) 1441-1452
    CrossrefPubMedGoogle Scholar
  • 34 Wang H-Y, Ding H-J, Chen J-H. et al. Meta-analysis of the diagnostic performance of [18F]FDG-PET and PET/CT in renal cell carcinoma. Cancer Imaging 2012; 12: 464-474
    CrossrefPubMedGoogle Scholar
  • 35 Liu Y. The place of FDG PET/CT in renal cell carcinoma: value and limitations. Front Oncol 2016; 6: 201
    PubMedGoogle Scholar
  • 36 Petrelli F, Coinu A, Vavassori I. et al. Cytoreductive nephrectomy in metastatic renal cell carcinoma treated with targeted therapies: a systematic review with a meta-analysis. Clin Genitourin Cancer 2016; 14 (06) 465-472
    CrossrefPubMedGoogle Scholar
  • 37 Pindoria N, Raison N, Blecher G, Catterwell R, Dasgupta P. Cytoreductive nephrectomy in the era of targeted therapies: a review. BJU Int 2017; 120 (03) 320-328
    CrossrefPubMedGoogle Scholar
  • 38 Amin MB, Greene FL, Edge SB. et al. The Eighth Edition AJCC Cancer Staging Manual: continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging. CA Cancer J Clin 2017; 67: 93-9
    CrossrefPubMedGoogle Scholar
  • 39 Ljungberg B, Albiges L, Abu-Ghanem Y. et al. European Association of Urology Guidelines on Renal Cell Carcinoma: the 2019 update. Eur Urol 2019; 75 (05) 799-810
    CrossrefPubMedGoogle Scholar
  • 40 Lane BR, Kattan MW. Prognostic models and algorithms in renal cell carcinoma. Urol Clin North Am 2008; 35 (04) 613-625 , vii vii
    CrossrefPubMedGoogle Scholar
  • 41 Sun M, Vetterlein M, Harshman LC, Chang SL, Choueiri TK, Trinh Q-D. Risk assessment in small renal masses: a review article. Urol Clin North Am 2017; 44 (02) 189-202
    CrossrefPubMedGoogle Scholar
  • 42 Martínez-Salamanca JI, Huang WC, Millán I. et al; International Renal Cell Carcinoma-Venous Thrombus Consortium. Prognostic impact of the 2009 UICC/AJCC TNM staging system for renal cell carcinoma with venous extension. Eur Urol 2011; 59 (01) 120-127
    CrossrefPubMedGoogle Scholar
  • 43 Margulis V, Sánchez-Ortiz RF, Tamboli P, Cohen DD, Swanson DA, Wood CG. Renal cell carcinoma clinically involving adjacent organs: experience with aggressive surgical management. Cancer 2007; 109 (10) 2025-2030
    CrossrefPubMedGoogle Scholar
  • 44 Tran J, Ornstein MC. Clinical review on the management of metastatic renal cell carcinoma. JCO Oncol Pract 2022; 18 (03) 187-196
    CrossrefPubMedGoogle Scholar
  • 45 Campbell SC, Novick AC, Belldegrun A. et al; Practice Guidelines Committee of the American Urological Association. Guideline for management of the clinical T1 renal mass. J Urol 2009; 182 (04) 1271-1279
    CrossrefPubMedGoogle Scholar
  • 46 Lee Z, Jegede OA, Haas NB. et al. Local recurrence following resection of intermediate-high risk nonmetastatic renal cell carcinoma: an anatomical classification and analysis of the ASSURE (ECOG-ACRIN E2805) adjuvant trial. J Urol 2020; 203 (04) 684-689
    CrossrefPubMedGoogle Scholar
  • 47 Thomas AZ, Adibi M, Borregales LD. et al. Surgical management of local retroperitoneal recurrence of renal cell carcinoma after radical nephrectomy. J Urol 2015; 194 (02) 316-322
    CrossrefPubMedGoogle Scholar
  • 48 Donat SM, Diaz M, Bishoff JT. et al. Follow-up for clinically localized renal neoplasms: AUA guideline. J Urol 2013; 190 (02) 407-416
    CrossrefPubMedGoogle Scholar
  • 49 Antonelli A, Furlan M, Tardanico R. et al. Features of ipsilateral renal recurrences after partial nephrectomy: a proposal of a pathogenetic classification. Clin Genitourin Cancer 2017; 15 (05) 540-547
    CrossrefPubMedGoogle Scholar
  • 50 Johnson A, Sudarshan S, Liu J, Linehan WM, Pinto PA, Bratslavsky G. Feasibility and outcomes of repeat partial nephrectomy. J Urol 2008; 180 (01) 89-93 , discussion 93
    CrossrefPubMedGoogle Scholar
  • 51 Marchioni M, Sountoulides P, Furlan M. et al. Management of local recurrence after radical nephrectomy: surgical removal with or without systemic treatment is still the gold standard. Results from a multicenter international cohort. Int Urol Nephrol 2021; 53 (11) 2273-2280
    CrossrefPubMedGoogle Scholar
  • 52 Itano NB, Blute ML, Spotts B, Zincke H. Outcome of isolated renal cell carcinoma fossa recurrence after nephrectomy. J Urol 2000; 164 (02) 322-325
    CrossrefPubMedGoogle Scholar
  • 53 Ierardi AM, Carnevale A, Rossi UG. et al. Percutaneous microwave ablation therapy of renal cancer local relapse after radical nephrectomy: a feasibility and efficacy study. Med Oncol 2020; 37 (04) 27
    CrossrefPubMedGoogle Scholar